October 26, 2011
Exposure to MS Drugs During Pregnancy: What is best for mother and baby?
- /
- /
By Julie Stachowiak, Ph.D., About.com Guide October 25, 2011 I have posted about this before, but I just got…
MS Views and News, empowers those affected by Multiple Sclerosis (MS) with educational information, resources and services. Please scroll downward to find articles or videos of interest, then click to open the document or video.
October 25, 2011
See, hear or do. What’s your favorite way to learn?
- /
Are you using your preferred style to enhance your learning abilities? In this issue of the MS LifeLines e-magazine, we…
October 25, 2011
Stopping natalizumab (Tysabri) to take a medication vacation, may mean renewed disease activity within six months
- /
- /
ECTRIMS: Fast MS Comeback May Ruin Drug ‘Holiday’ This report is part of a 12-month Clinical Context series. By John Gever,…
October 22, 2011
Cognitive Decline, Brain Atrophy More Rapid for Men With MS
- /
- /
- /
October 20, 2011 (Amsterdam, the Netherlands) — A new investigation finds that 6 years after diagnosis, brain volumes and, particularly,…
October 22, 2011
Multiple sclerosis diagnosis turned her life upside-down
- /
- /
Imagine waking up numb. So numb, in fact, that movement is either impossible or takes all your energy. If you…
October 22, 2011
In study, Lemtrada helps MS patients
- /
- /
Oct 22, 2011 New data from a late-stage trial showed that 78 percent of patients treated with Lemtrada remained relapse-free…
October 22, 2011
One of the scientists at Biogen Idec pushing for a new kind of regenerative medicine for Multiple Sclerosis
- /
- /
- /
Luke Timmerman 10/21/11 Sha Mi, Biogen Idec’s Neurology Ace, to Join “The Genetics Institute Impact” conference One of the scientists at…
October 22, 2011
Genentech announces 96-week results from ocrelizumab Phase II study on RRMS
- /
- /
October 21, 2011 Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced 96-week results from…
October 22, 2011
Clinical and MRI Outcomes in Patients With MS, Treated with Fingolimod
- /
- /
- /
AMSTERDAM—Fingolimod at an oral dose of 0.5 mg consistently improved relapse rates, disability, and MRI outcomes compared with placebo or…
October 22, 2011
Approximately One-Third of MS Patients Experiencing Relapses Do Not Adequately Respond to Traditional Corticosteroid Therapy
- /
- /
–Survey conducted by the North American Research Committee on Multiple Sclerosis (NARCOMS)– AMSTERDAM, Oct. 21, 2011 /PRNewswire/ — On October 21 at the 5th Joint…
